Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735711 | 1.00 | HTT (0.56) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL735949 | 1.00 | HTT (0.56) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL10403301 | 0.87 | HTT (0.55) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL8745665 | 0.85 | HTT (0.61) | HTTLMNASMN1; SMN2TGM2KMT2A | |
| SCHEMBL5019087 | 0.84 | LMNA (0.61) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL14019069 | 0.84 | LMNA (0.66) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL10403814 | 0.84 | LMNA (0.54) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL29951926 | 0.84 | LMNA (0.54) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL734467 | 0.82 | LMNA (0.52) | HTTLMNASMN1; SMN2TGM2SYK | |
| SCHEMBL734465 | 0.82 | LMNA (0.52) | HTTLMNASMN1; SMN2TGM2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522905-A | Enzymatic chemical process for preparing iminocyclitols | CONSEJO SUPERIOR INVESTIGACION (ES) | 2009-09-02 | — | — | CN | claimed |
| EP-3883943-A1 | MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME | Technion Research & Development Foundation Limited (IL) | 2021-09-29 | — | — | EP | disclosed |
| WO-2020105054-A9 | MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2020-11-05 | — | — | WO | disclosed |
| EP-2307387-B1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8071586-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2321285-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2307387-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010012619-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
| CN-101522905-A | Enzymatic chemical process for preparing iminocyclitols | CONSEJO SUPERIOR INVESTIGACION (ES) | 2009-09-02 | — | — | CN | disclosed |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS AG | 2008-08-28 | — | — | US | disclosed |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS AG | 2008-08-28 | — | — | US | disclosed |
| WO-2008086122-A2 | IMIDAZOLE DERIVATIVES AS KINESIN SPINDLE PROTEIN INHIBITORS (EG-5) | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | HTT 4172/4885LMNA 3760/4885SMN1; SMN2 4455/4885 |
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | HTT 1665/4885LMNA 3624/4885SMN1; SMN2 4796/4885 |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | HTT 4298/4885LMNA 3407/4885SMN1; SMN2 4376/4885 |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | HTT 1665/4885LMNA 3624/4885SMN1; SMN2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.